8:110.
8. Carpentier PH, Maricq HR, Biro C, Poncot-Makinen CO, Franco A.
Prevalence, risk factors and clinical patterns of chronic venous disorders of lower limbs. A population-based study in France. J Vasc Surg
2004;40:650-9.
9. Rabe E, Pannier-Fischer F, Bromen K, Schuldt K, Stang A, Poncar C,
et al. Bonner Venenstudie der Deutschen Gesellschaft für Phlebologieepidemiologische Untersuchung zur Frage der Häuﬁgkeit und
Ausprägung von chronischen Venenkrankheiten in der städtischen
und ländlichen Wohnbevölkerung. Phlebologie 2003;32:1-14.
10. McLafferty RB, Passman MA, Caprini JA, Rooke TW, Markwell SA,
Lohr JM, et al. Increasing awareness about venous disease: The
American Venous Forum expands the National Venous Screening
Program. J Vasc Surg 2008;48:394-9.
11. Rhodes JM, Gloviczki P, Canton LG, Rooke T, Lewis BD,
Lindsey JR. Factors affecting clinical outcome following endoscopic
perforator vein ablation. Am J Surg 1998;176:162-7.
12. Nelzen O. Leq ulcers: Economic Aspects. Cost effectiveness analysis
of leg ulcers. Phlebology 2000;15:110-4.
13. Rippon M, Davies P, White R, Bosanquet N. The economic impact of
hard-to-heal leg ulcers. Wounds UK 2007;3:58-69.

O’Donnell et al 47S

14. Simka M, Majewski E. The social and economic burden of venous leg
ulcers: Focus on the role of micronized puriﬁed ﬂavonoid fraction
adjuvant therapy. Am J Clin Dermatol 2003;4:573-81.
1